Tivozanib (Fotiva®): First Global Approval – selective agent for optimal VEGF blockade in adults with renal cell carcinoma.

Tivozanib (Fotiva®): First Global Approval – selective agent for optimal VEGF blockade in adults with renal cell carcinoma.

The recent first global approval of tivozanib has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Tivozanib (Fotiva®): First Global Approval – selective agent for optimal VEGF blockade in adults with renal cell carcinoma.”

Glecaprevir/Pibrentasvir (MAVIRET™): First Global Approval in Europe – then BAM! Anti-viral approval spreads rapidly across the globe!!

Glecaprevir/Pibrentasvir (MAVIRET™): First Global Approval in Europe – then BAM! Anti-viral approval spreads rapidly across the globe!!

The recent first global approval of glecaprevir/pibrentasvir has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Glecaprevir/Pibrentasvir (MAVIRET™): First Global Approval in Europe – then BAM! Anti-viral approval spreads rapidly across the globe!!”

Pemafibrate (Parmodia®): First Global Approval – second (PPAR)-α agonist joins Japanese market in a bid to tip the lipoprotein cholesterol balance

Pemafibrate (Parmodia®): First Global Approval –  second (PPAR)-α agonist joins Japanese market in a bid to tip the lipoprotein cholesterol balance

The recent first global approval of pemafibrate has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Pemafibrate (Parmodia®): First Global Approval – second (PPAR)-α agonist joins Japanese market in a bid to tip the lipoprotein cholesterol balance”